Drug Trial Radar · NCT05604261
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
156
Planned (sponsor's estimate)
Start
Dec 2022
Primary completion
Jul 2023
Study completion Mar 2024
Sponsor
- Lead sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.
Conditions
- Reflux Esophagitis
- Gastroesophageal Reflux
- Esophagitis
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Gastrointestinal Diseases
Interventions
Anaprazole sodium 40 mgDrug
Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Anaprazole sodium 60 mgDrug
Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Rabeprazole sodium 20 mgDrug
Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The endoscopic healing rate of reflux esophagitis within 8 weeks (including 8 weeks)Time frame: Treatment of 4 weeks or 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.